Major drug makers, including Pfizer and Amgen, are set to open or expand operations in Hong Kong. These industry leaders, spanning fintech and cloud computing, are part of a larger group of 22 strategic firms looking to establish a presence in the region.

Global drug maker Pfizer and biotech firm Amgen, each valued at over HK$1 trillion (US$153 billion), are among 22 strategic enterprises planning to open or expand offices in Hong Kong, the South China Morning Post has learned. A source said on Monday that these industry leaders were among companies from the fintech, cloud computing and aerial transport sectors set to sign agreements with the Office for Attracting Strategic Enterprises. The move will mark the sixth cohort under the government’s.....